This update provides a link to the NCI page that lists the labs participating with the five principal centers.
NEW YORK (GenomeWeb News) – The National Cancer Institute today unveiled a $104 million Clinical Proteomic Technologies Initiative for Cancer.
NCI awarded a total of $35.5 million in grants over five years to establish a network of five teams for Clinical Proteomic Technology Assessment for Cancer, the agency said. The teams comprise: the Broad Institute of MIT and Harvard; University of California San Francisco/Lawrence Berkeley National Laboratory; Vanderbilt University School of Medicine; Purdue University; and Memorial Sloan-Kettering Cancer Center.
Each team will assess measurement technologies for proteins and peptides relevant to clinical cancer research and practice. Specifically, they will assess mass spectrometry and affinity capture platforms and evaluate the performance of various proteomic technology platforms. A list of the teams that comprise each of the five labs can be found here.
The NCI said standards will allow researchers conducting cancer-related protein research at different labs to use proteomic technologies and methodologies to directly compare and analyze their work.